Role of agents other than tumor necrosis factor blockers in the treatment of psoriatic arthritis

Fabiola Atzeni; Luisa Costa; Francesco Caso; Raffaele Scarpa; Piercarlo Sarzi-Puttini

doi:10.3899/jrheum.150643

Role of agents other than tumor necrosis factor blockers in the treatment of psoriatic arthritis

Fabiola Atzeni, Luisa Costa, Francesco Caso, Raffaele Scarpa, Piercarlo Sarzi-Puttini

IRCCS Istituto Ortopedico Galeazzi

Research output: Contribution to journal › Article

Abstract

Psoriatic arthritis (PsA) is a systemic inflammatory disease characterized by possible peripheral and axial joint involvement, enthesitis, dactylitis, and skin and nail disease. It affects up to one-third of psoriatic patients, and may be associated with comorbidities such as cardiovascular and metabolic diseases. The usually prescribed initial treatment of moderate-severe PsA is methotrexate, which may be accompanied or replaced by a tumor necrosis factor (TNF) inhibitor such as etanercept, infliximab, or adalimumab. However, some patients may become unresponsive (or have contraindications) to available anti-TNF agents and require alternative treatment. The aim of this review is to describe the potential role of some new immunomodulatory agents. The Journal of Rheumatology

Original language	English
Pages (from-to)	79-81
Number of pages	3
Journal	Journal of Rheumatology
Volume	93
DOIs	https://doi.org/10.3899/jrheum.150643
Publication status	Published - Nov 1 2015

Keywords

Apremilast
Interleukin-17 inhibitors
Psoriatic arthritis
Rituximab
Tumor necrosis factor inhibitors
Ustekinumab

ASJC Scopus subject areas

Rheumatology
Immunology
Immunology and Allergy

Access to Document

10.3899/jrheum.150643

Fingerprint Dive into the research topics of 'Role of agents other than tumor necrosis factor blockers in the treatment of psoriatic arthritis'. Together they form a unique fingerprint.

Cite this

Atzeni, F., Costa, L., Caso, F., Scarpa, R., & Sarzi-Puttini, P. (2015). Role of agents other than tumor necrosis factor blockers in the treatment of psoriatic arthritis. Journal of Rheumatology, 93, 79-81. https://doi.org/10.3899/jrheum.150643

@article{dad86d4e49c34ee49ee54d10e00ff6f4,

title = "Role of agents other than tumor necrosis factor blockers in the treatment of psoriatic arthritis",

abstract = "Psoriatic arthritis (PsA) is a systemic inflammatory disease characterized by possible peripheral and axial joint involvement, enthesitis, dactylitis, and skin and nail disease. It affects up to one-third of psoriatic patients, and may be associated with comorbidities such as cardiovascular and metabolic diseases. The usually prescribed initial treatment of moderate-severe PsA is methotrexate, which may be accompanied or replaced by a tumor necrosis factor (TNF) inhibitor such as etanercept, infliximab, or adalimumab. However, some patients may become unresponsive (or have contraindications) to available anti-TNF agents and require alternative treatment. The aim of this review is to describe the potential role of some new immunomodulatory agents. The Journal of Rheumatology",

keywords = "Apremilast, Interleukin-17 inhibitors, Psoriatic arthritis, Rituximab, Tumor necrosis factor inhibitors, Ustekinumab",

author = "Fabiola Atzeni and Luisa Costa and Francesco Caso and Raffaele Scarpa and Piercarlo Sarzi-Puttini",

year = "2015",

month = nov,

day = "1",

doi = "10.3899/jrheum.150643",

language = "English",

volume = "93",

pages = "79--81",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

}

TY - JOUR

T1 - Role of agents other than tumor necrosis factor blockers in the treatment of psoriatic arthritis

AU - Atzeni, Fabiola

AU - Costa, Luisa

AU - Caso, Francesco

AU - Scarpa, Raffaele

AU - Sarzi-Puttini, Piercarlo

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Psoriatic arthritis (PsA) is a systemic inflammatory disease characterized by possible peripheral and axial joint involvement, enthesitis, dactylitis, and skin and nail disease. It affects up to one-third of psoriatic patients, and may be associated with comorbidities such as cardiovascular and metabolic diseases. The usually prescribed initial treatment of moderate-severe PsA is methotrexate, which may be accompanied or replaced by a tumor necrosis factor (TNF) inhibitor such as etanercept, infliximab, or adalimumab. However, some patients may become unresponsive (or have contraindications) to available anti-TNF agents and require alternative treatment. The aim of this review is to describe the potential role of some new immunomodulatory agents. The Journal of Rheumatology

AB - Psoriatic arthritis (PsA) is a systemic inflammatory disease characterized by possible peripheral and axial joint involvement, enthesitis, dactylitis, and skin and nail disease. It affects up to one-third of psoriatic patients, and may be associated with comorbidities such as cardiovascular and metabolic diseases. The usually prescribed initial treatment of moderate-severe PsA is methotrexate, which may be accompanied or replaced by a tumor necrosis factor (TNF) inhibitor such as etanercept, infliximab, or adalimumab. However, some patients may become unresponsive (or have contraindications) to available anti-TNF agents and require alternative treatment. The aim of this review is to describe the potential role of some new immunomodulatory agents. The Journal of Rheumatology

KW - Apremilast

KW - Interleukin-17 inhibitors

KW - Psoriatic arthritis

KW - Rituximab

KW - Tumor necrosis factor inhibitors

KW - Ustekinumab

UR - http://www.scopus.com/inward/record.url?scp=84951790429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951790429&partnerID=8YFLogxK

U2 - 10.3899/jrheum.150643

DO - 10.3899/jrheum.150643

M3 - Article

C2 - 26523064

AN - SCOPUS:84951790429

VL - 93

SP - 79

EP - 81

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

ER -